Aurinia Pharmaceuticals (AUPH) Income from Continuing Operations (2019 - 2026)
Aurinia Pharmaceuticals (AUPH) posted Income from Continuing Operations of 34355000.0 for Q1 2026, down 83.7% on a QoQ basis from 210794000.0 in Q4 2025, and up 47.17% year-over-year from 23344000.0 in Q1 2025.
Aurinia Pharmaceuticals (AUPH) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Aurinia Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 34355000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 47.17% year-over-year to 34355000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 298267000.0 (up 648.47% YoY) and the FY2025 annual result came in at 287202000.0, up 4893.08% from the prior year.
- Income from Continuing Operations was 34355000.0 for Q1 2026 at Aurinia Pharmaceuticals, down from 210794000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 210794000.0 in Q4 2025 and bottomed at 37630000.0 in Q1 2022.
- A 5-year average of 8308294.12 and a median of 8989000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 49.62% — and 2025, when it jumped 14171.77%.
- Aurinia Pharmaceuticals' Income from Continuing Operations stood at 26018000.0 in 2022, then slipped by 3.26% to 26867000.0 in 2023, then soared by 105.5% to 1477000.0 in 2024, then soared by 14171.77% to 210794000.0 in 2025, then sank by 83.7% to 34355000.0 in 2026.
- Business Quant data shows AUPH's Income from Continuing Operations at 34355000.0 in Q1 2026, 210794000.0 in Q4 2025, and 31562000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | 34.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.36 Mn |
| Dec 31, 2025 | 210.79 Mn |
| Sep 30, 2025 | 31.56 Mn |
| Jun 30, 2025 | 21.56 Mn |
| Mar 31, 2025 | 23.34 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 14.31 Mn |
| Jun 30, 2024 | 722,000.00 |
| Mar 31, 2024 | -10.71 Mn |
| Dec 31, 2023 | -26.87 Mn |
| Sep 30, 2023 | -13.45 Mn |
| Jun 30, 2023 | -11.49 Mn |
| Mar 31, 2023 | -26.21 Mn |
| Dec 31, 2022 | -26.02 Mn |
| Sep 30, 2022 | -8.99 Mn |
| Jun 30, 2022 | -35.52 Mn |
| Mar 31, 2022 | -37.63 Mn |
| Dec 31, 2021 | -33.32 Mn |
| Sep 30, 2021 | -50.26 Mn |
| Jun 30, 2021 | -47.01 Mn |